The United Kingdom and the United States have established a major bilateral deal that will preserve zero tariffs on British medicine shipments being sold in the American market.
The Terms of the Pact
As part of the deal, the UK has agreed to increase spending on medicines through the NHS. This commitment ensures that duties on these vital exports will be held at nothing for a period of the next three years.
This deal comes after previous threats to hike duties on patented drug products, with potential rates floated as high as double the cost.
"This deal with the Britain bolsters the global environment for innovative medicines and brings much-needed fairness to transatlantic drug exports," a statement declared.
Commercial Impact
Drugs are one of the Britain's largest goods shipped to the America, which is by far the largest market for large British pharmaceutical firms.
Statistics indicate that in the one-year period leading up to September, the UK sold pharmaceutical products worth £11.1bn to the US. This amount accounted for 17.4% of British export trade in that span.
"This guarantee protects employment, boosts funding and paves the way for the UK to become a worldwide center for life sciences," the Business and Trade Secretary remarked.
Detailed UK Commitments
The deal involves several notable commitments from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on treatments from 0.3% of the national economy to 0.6% over the coming ten years.
- Payback Limit: The amount drug companies must pay back to the NHS to control costs will be capped at 15%. Previously, rebates were more than 20%.
Broader Context
The deal follows a long-running dispute between the drug companies and the ministers over drug pricing and NHS adoption.
These tensions were heightened by assertions that US customers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or cancelled, while substantial funding commitments have been directed toward US facilities.
The Science Minister stated that the NHS had to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the past decade.
